Galderma Forecast, price target & analysts
Galderma Target price 2025 - Analyst rating & recommendation
Galderma Classifications & Recommendation:
Galderma Price Target
| Target Price | CHF109.43 |
| Price | CHF93.25 |
| Potential |
17.35%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Galderma 2026 .
The average Galderma target price is CHF109.43.
This is
17.35%
register free of charge
CHF116.18
24.59%
register free of charge
CHF100.21
7.46%
register free of charge
|
|
| A rating was issued by 13 analysts: 9 Analysts recommend Galderma to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2026 of
17.35%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 3.88 | 4.04 |
| 5.88% | 3.95% | |
| EBITDA Margin | 21.34% | 22.64% |
| 2.16% | 6.10% | |
| Net Margin | 5.26% | 9.22% |
| 469.20% | 75.38% |
11 Analysts have issued a sales forecast Galderma 2025 . The average Galderma sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Galderma EBITDA forecast 2025. The average Galderma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Galderma Analysts have issued a net profit forecast 2025. The average Galderma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 0.86 | 1.57 |
| 490.91% | 82.56% | |
| P/E | 59.46 | |
| EV/Sales | 6.00 |
8 Analysts have issued a Galderma forecast for earnings per share. The average Galderma EPS is
This results in the following potential growth metrics and future valuations:
Current Galderma Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
| BNP PARIBAS EXANE |
Locked
➜
Locked
|
Locked | Aug 21 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Nov 25 2024 |
|
Locked
BNP PARIBAS EXANE:
Locked
➜
Locked
|
Aug 21 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
